Prohost Comprehensive Letter #450 BEAR MARKET. BAD MARKET. UNPREDICTABLE MARKET. Stock market investors usually learn from responsible sources about the status of the factors influencing the country’s economy. This is not what’s going on today. Investors have been unaware of the facts and factors that influence the economy, which includes the soaring inflation, crude oil and gas prices, the true future of COVID-19, the Russian …

Comprehensive Prohost Letter Issues Reality The Best of words in informative texts are the smallest in number and the most truthful in contents. That’s what Prohost believes, especially in the presence of the cruel circumstances our entire planet is currently living. Last Friday, the three indexes of the stock market had their best performances since the 4th quarter of 2020. Why? We don’t know, but …

Some Gains in Biotech Stocks During the War in Europe On Tuesday, Mar 8,2022 the United States’ government decided to ban the importation of Russian oil, liquefied natural gas and coal. This decision was made to further deprive Russia from the resources that enable it to continue with the unwarranted war against Ukraine. This resolution has come at a time when the price of oil …

Intellia Therapeutics Statement on Recent U.S. Patent and Trademark Office Decision – In May 2012, the Regents of University of California, University of Vienna, and Emmanuelle Charpentier (collectively, “CVC”) filed a patent application for their CRISPR/Cas9 genome editing technology. The CVC team led by Drs. Jennifer Doudna and Emmanuelle Charpentier promptly brought these discoveries to the public, and in June 2012 published a seminal paper …

Intellia Therapeutics Loses Technology Patent and Suffers a Selloff A selloff of Intellia Therapeutics (NTLA) stock occured when the U.S. Patent and trademark office ruled that CRISPR genome editing technology patent belongs to the Broad Institute. It's stating that a team of researchers led by Feng Zhang beat Jennifer Doudna and Emmanuelle Charpentier in making CRISPR editing possible. This new . . . This content …

Intellia Therapeutics Acquires Rewrite Therapeutics The acquisition is, indeed good news. By acquiring Rewrite Therapeutics, Intellia Therapeutics (NTLA) has inherited a versatile DNA writing platform which enables a range of innovative genome editing strategies. The acquisition is expected to further expand Intellia’s industry-leading genome editing toolbox by adding a highly complementary platform to its existing CRISPR/Cas9 and . . . This content is for paid …

We Are Back! Thanks to God. Hello to all our subscribers. Our sickness was unanticipated, making our year start in February rather than January. We will tackle the sickness later in another article. Now it is time to appreciate and offer our love and thanks from the bottom of our hearts for those who wished us well, prayed for our recovery and made it happen. …

The Bizarre Assessment of Biotech Firms in the Stock Market The Clinical-Stage Biotechnology Firms  We are witnessing inexplicable evaluations of clinical-stage biotechnology companies. Bizarre is the best description of this group’s assessment which is based on incomes that do not exist in biotech firms that are yet to have approved and marketed products anywhere in the world. Unfortunately, the most impacted firms by the bizarre …

Intellia Therapeutics to Present at ASH Intellia Therapeutics (NTLA) announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Atlanta, GA, as well as virtually, December 11-14, 2021. From the CSO at Intellia Therapeutics Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer, Intellia Therapeutics, said, “As we continue to …

Intellia Therapeutics Granted Orphan Drug Designation for NTLA-2001 Intellia Therapeutics (NTLA) announced that the U.S. FDA has granted orphan drug designation to NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis. This investigational therapy is the first CRISPR therapy to be administered systemically to edit a disease-causing gene inside the human body. NTLA-2001 has the potential to be the first single-dose treatment for ATTR amyloidosis as it …

Intellia Therapeutics and SparingVision Collaboration Intellia Therapeutics (NTLA) and SparingVision - a genomic medicine company developing vision saving treatments for ocular diseases, announced a strategic collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Intellia Therapeutics is to grant SparingVision exclusive rights to Intellia . . . This content is for paid subscribers. Please click here to subscribe or here to …

Denali Therapeutics News Denali Therapeutics (DNLI) -  a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases.  Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San . . . This content is for …

Intellia Therapeutics Authorization of CTA for Phase 1/2 Study of NTLA-2002 Intellia Therapeutics (NTLA) announced the authorization of its Clinical Trial Application (CTA) by the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) to initiate a Phase 1/2 study evaluating NTLA-2002 for the treatment of adults with hereditary angioedema (HAE). About Hereditary . . . This content is for paid subscribers. Please click here to subscribe or …

The Comprehensive Prohost Letter Issues The Comprehensive Prohost Letter Issues will constitute a chain of 7 issues. Today’s issue will include the following: Pinpointing and selecting the biotech firms that demonstrate readiness to treat untreatable, devastating diseases. Presenting an important antibody cocktail for the treatment of COVID-19. Stating our position regarding the Alzheimer’s disease firm Cassava Sciences. Pinpointing Prohost’s . . . This content is …

Intellia Therapeutics IND Application of NTLA-5001 for AML is Accepted by the US FDA NTLA-5001 is Intellia Therapeutics (NTLA) first wholly-owned ex vivo CRISPR genome editing candidate for the treatment of cancer. It is an autologous T cell receptor (TCR)-T cell therapy engineered to target the Wilms’ Tumor (WT1) antigen for the treatment of all genetic subtypes . . . This content is for paid …

Agenus Inc News and Q2 Results for 201 Agenus (AGEN) announced results with better than usual news including the following:  $200 million received from BMS for anti-TIGIT bispecific antibody collaboration FDA cleared IND for AGEN1777 clinical enrollment AGEN1181 rapidly advancing in the clinic - data to be presented in 2H 2021 Cell therapy . . . This content is for paid subscribers. Please click here to …

Prohost Letter #446 A Reevaluation of Prohost Biotech’s Picked Firms We have already pinpointed some of the devastating and life-threatening diseases that have yet to find treatment. Prohost’s plans are about discovering small &/or large biotech or biopharma firms that demonstrate scientific capability for treating or curing these diseases. Most of the firms that we picked for investment in yesteryears had solid scientific and managerial …

bluebird bio Receives EC Approval for  bluebird bio (BLUE) announced that the European Commission (EC) has granted marketing authorization of SKYSONA™ (elivaldogene autotemcel, Lenti-D™) one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age with an ABCD1 genetic mutation, and for whom a human leukocyte antigen . . . This content is for paid subscribers. Please click here to subscribe or here to …

Prohost Portfolio PLUS #7 Companies Behind The Biotechnology Revolution Without these firms, basic science discoveries in the universities and the academic institutions and by the firms themselves would remain unutilized and shelved. Most of the firms we picked for the Prohost Portfolio are bringing novel products to newly discovered targets, and most have offered proof of concept of their hypotheses. Having said that, we add …

Prohost Portfolio PLUS #6 Yes, it is a Miracle! Intellia Therapeutics and Regeneron Pharmaceuticals This miracle news from Intellia Therapeutics and Regeneron Pharmaceuticals came Saturday, a day when the Market is taking rest from the usual yo-yoing of good/bad reasons and no reasons. This miracle of great news emanated from Intellia Therapeutics. The first-ever clinical data from a trial that supports safety and efficacy of in vivo CRISPR …